Asia-Pacific Human Insulin Market Research Report: Forecast (2024-2030)

Asia-Pacific Human Insulin Market - By Type (Human Insulin Biologics, Intermediate Acting, Short Acting, Premixed), Insulin Analogue & Biosimilar, [Long Acting, Rapid Acting, Premi......xed]), By Application, (Diabetes Type 1, Diabetes Type 2), By End Users (Hospital/Clinics, Home/Personal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Others Read more

  • Healthcare
  • Feb 2024
  • 150
  • PDF, Excel, PPT

Market Definition

Insulin is a hormone produced by the pancreas that regulates blood sugar levels in the body. It mainly functions by aiding the transfer of sugar from the bloodstream to various body tissues, where it is utilized as energy. In medicine, human insulin is commonly manufactured using genetic engineering methods. This synthetic insulin is indistinguishable from the insulin naturally created by the human body. It is employed in diabetes treatment to substitute or complement the body's insulin production, aiding in the management of blood sugar levels & the prevention of diabetes-related complications.

Market Insights & Analysis: Asia-Pacific Human Insulin Market (2024-30):

The Asia-Pacific Human Insulin Market is estimated to grow at a CAGR of around 8.12% during the forecast period, i.e., 2024-30. The region is home to a large & rapidly growing population affected by diabetes. Urbanization, sedentary lifestyles, unhealthy dietary habits, and an aging population contribute to the increasing prevalence of diabetes in countries across the region. As diabetes rates soar, there is a growing need for accessible & affordable diabetes management solutions, including human insulin therapy.

Report Coverage Details
Study Period Historical Data: 2019-22
Base Year: 2023
Forecast Period: 2024-30
CAGR (2024-30) 8.12%
Country Covered China, India, Japan, Thailand, Australia, South Korea, Rest of Asia-Pacific
Key Companies Profiled Becton, Dickinson and Company (BD), Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Wockhardt Limited, Lupin Limited, Novo Nordisk A/S, Eris Lifesciences, Sanofi, Tonghua Dongbao Pharmaceutical Co., Ltd, and others
Market Value USD Million/Billion

 

Moreover, the demand for human insulin has improved over the years, which has been mainly attributed to the rising prevalence of gestational diabetes in pregnant women. Notably, this condition is more prevalent in low- & middle-income countries where access to maternal care is limited. Gestational diabetes mellitus (GDM) is the elevated blood sugar levels during pregnancy, typically resolving after childbirth. During pregnancy, the placenta generates hormones that disrupt the body's insulin utilization, a normal occurrence in gestation known as insulin resistance. Hence, as the instance of gestational diabetes has been amplifying across the region, the demand for human insulin has also increased.

Furthermore, increasing government initiatives and support for expanding & modernizing healthcare infrastructure are aimed at meeting the rising demand for diabetes care. This includes establishing specialized diabetes clinics, endocrinology departments, and diabetes centers equipped with advanced diagnostic and treatment facilities. Thus, the expansion of healthcare infrastructure is enhancing access to human insulin therapy for patients with diabetes, further driving market growth in the coming years.

  1. Market Segmentation
  2. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  3. Executive Summary
  4. Asia-Pacific Human Insulin Market Policy & Regulations
  5. Asia-Pacific Human Insulin Market Trends & Development
  6. Asia-Pacific Human Insulin Market Dynamics
    1. Drivers
    2. Challenges
  7. Asia-Pacific Human Insulin Market Hotspots & Opportunities
  8. Asia-Pacific Human Insulin Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Type
        1. Human Insulin Biologics - Market Size & Forecast 2019-2030, USD Million
          1. Intermediate Acting- Market Size & Forecast 2019-2030, USD Million
          2. Short Acting- Market Size & Forecast 2019-2030, USD Million
          3. Premixed- Market Size & Forecast 2019-2030, USD Million
        2. Insulin Analogue & Biosimilar - Market Size & Forecast 2019-2030, USD Million
          1. Long Acting- Market Size & Forecast 2019-2030, USD Million
          2. Rapid Acting- Market Size & Forecast 2019-2030, USD Million
          3. Premixed- Market Size & Forecast 2019-2030, USD Million
      2. By Application
        1. Diabetes Type 1- Market Size & Forecast 2019-2030, USD Million
        2. Diabetes Type 2- Market Size & Forecast 2019-2030, USD Million
      3. By End Users
        1. Hospital/Clinics- Market Size & Forecast 2019-2030, USD Million
        2. Home/Personal- Market Size & Forecast 2019-2030, USD Million
      4. By Distribution Channel
        1. Hospital Pharmacies- Market Size & Forecast 2019-2030, USD Million
        2. Retail Pharmacies- Market Size & Forecast 2019-2030, USD Million
        3. Online Pharmacies- Market Size & Forecast 2019-2030, USD Million
      5. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South Korea
        6. Thailand
        7. Rest of Asia-Pacific
      6. By Company
        1. Competition Characteristics
        2. Market Share and Analysis, By Revenues
  9. China Human Insulin Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Type- Market Size & Forecast 2019-2030, USD Million
      2. By Application- Market Size & Forecast 2019-2030, USD Million
  10. Japan Human Insulin Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Type- Market Size & Forecast 2019-2030, USD Million
      2. By Application- Market Size & Forecast 2019-2030, USD Million
  11. India Human Insulin Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Type- Market Size & Forecast 2019-2030, USD Million
      2. By Application- Market Size & Forecast 2019-2030, USD Million
  12. Australia Human Insulin Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Type- Market Size & Forecast 2019-2030, USD Million
      2. By Application- Market Size & Forecast 2019-2030, USD Million
  13. South Korea Human Insulin Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Type- Market Size & Forecast 2019-2030, USD Million
      2. By Application- Market Size & Forecast 2019-2030, USD Million
  14. Thailand Human Insulin Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Type- Market Size & Forecast 2019-2030, USD Million
      2. By Application- Market Size & Forecast 2019-2030, USD Million
  15. Asia-Pacific Human Insulin Market Key Strategic Imperatives for Success & Growth
  16. Competitive Outlook
    1. Company Profile
      1. Novo Nordisk A/S
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      2. Eli Lilly and Company
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      3. Sanofi
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      4. Biocon
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      5. Gan & Lee Pharmaceuticals Co. Ltd
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      6. Wockhardt
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      7. Lupin
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      8. Eris Lifesciences Ltd
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      9. Tonghua Dongbao Pharmaceutical Co., Ltd.
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      10. The United Laboratories International Holdings Limited
        1. Business Description
        2. Solution Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      11. Others
  17. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO GET THE FREE SAMPLE PAGES

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now
Inquire Before Buying Inquire Before Buying
Related Reports
Talk to our Consultant Talk to our Consultant
Customization Offered
  • Cross-segment Market Size & Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics & Share
  • Import Export & Production Analysis
Request Customization Request Customization